View live charts, options flow & technicals for Becton, Dickinson and Company →
Open Dashboard
Becton, Dickinson and Company (BDX) is a healthcare company in the medical instruments & supplies industry with $22.48B in trailing revenue trading at a 31.6× trailing P/E — analyst consensus: buy.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Key Statistics
Market Cap
$49.72B
Revenue (TTM)
$22.48B
EPS (TTM)
$5.77
EPS (Fwd est.)
$13.29
Employees
72,000
Trailing P/E
31.63
Forward P/E
13.73
PEG Ratio
1.11
Price / Sales
2.21
Price / Book
2.04
EV / EBITDA
10.75
Beta (5Y)
0.28
Analyst Consensus
Consensus
Buy
Analyst Price Target
+7.2% upside
Target: $195.67
Annual Revenue & Net Income
RevenueNet Income
'22
$18.87B
$1.78B
'23
$19.37B
$1.48B
'24
$20.18B
$1.71B
'25
$21.84B
$1.68B
Earnings History
Quarter
Actual EPS
Estimate
Result
Aug 2026
$3.23
$3.14
Beat (+2.9%)
May 2026
$2.90
$2.77
Beat (+4.5%)
Feb 2026
$2.91
$2.81
Beat (+3.5%)
Nov 2025
$3.96
$3.91
Beat (+1.1%)
Next Earnings Report
Becton, Dickinson and Company is next expected to report earnings on 05 Nov 2026.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segmen…
What is BDX's market cap?
Becton, Dickinson and Company has a market capitalization of approximately $49.72B.
What is BDX's P/E ratio?
Becton, Dickinson and Company trades at a trailing P/E ratio of 31.6x and a forward P/E of 13.7x, which is above the broad market average of ~25x.
How much revenue does BDX generate?
Becton, Dickinson and Company generated $22.48B in trailing 12-month revenue.
What do analysts say about BDX?
The analyst consensus rating for Becton, Dickinson and Company is buy, with a mean price target of $195.67. That implies +7.2% upside from the current price.
When does BDX report earnings?
Becton, Dickinson and Company is next scheduled to report earnings on 05 Nov 2026.
Does BDX pay a dividend?
Yes. Becton, Dickinson and Company pays a dividend with a current yield of 2.30%, at an annual rate of $4.20 per share.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Becton, Dickinson and Company on Apsis Markets.